Navigation Links
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:3/28/2008

EF="http://www.eisai.co.jp/index-e.html" target="_new">http://www.eisai.co.jp/index-e.html.

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ended March 31, 2007). For more information about Eisai Inc., please visit http://www.eisai.com.

About Aricept(R)

Aricept(R) is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell their doctors because serious stomach problems, such as bleeding, may get worse. Some people who take Aricept(R) may experience fainting. Some people may have nausea, vomiting, diarrhea, bruising, or not sleep well. Some people may have muscle cramps or loss of appetite or may feel tired. In studies, these were usually mild and temporary.

In a progressively degenerative disease such as Alzheimer's, improvement, stabilization or a less-than-expected decline over time is considered a positive response to treatment. These types of responses have been observed in patients treated with Aricept(R) in clinical trials for Alzheimer's disease. Individual responses to treatment vary. For more information about Aricept(R), see accompanying full prescribing information or call (888) 999-9616 or visit http://www.aricept.com.

Safe Harbor Statement

This press release may contain so-called "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and mark
'/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
2. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
3. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
4. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
5. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
6. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
7. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
8. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
, , , , back to top...
... Faye Boeckman, Marni Brisson, and Larissa Tan, Bio-Rad Laboratories, Inc.,Hercules CA 94547 USA ... , General Information , ... a versatile tool , in molecular biology. The ... advances in gene discovery, diagnostics, and gene expression analysis. , ...
... Psychiatry Research, , 130 West Kingsbridge Road, ... Introduction , ... population (Strange 1992). Patients experience a variety of ... of positive symptoms (e.g., thought disorder, , abnormal ...
Cached Biology Technology:Real-Time PCR: General Considerations, Rev A 2Real-Time PCR: General Considerations, Rev A 3Real-Time PCR: General Considerations, Rev A 4Real-Time PCR: General Considerations, Rev A 5Real-Time PCR: General Considerations, Rev A 6Real-Time PCR: General Considerations, Rev A 7Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 2Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 3Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 4Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 5Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 6Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 7Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 8Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 9Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A 10
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... neonatal illness in piglets is coccidiosis, a parasitic disease ... Isospora suis . There are many reasons ... welfare considerations to pure financial concerns. Unfortunately, however, ... should be done. Sulfonamides are frequently suggested as ...
... of the measurements will be used to evaluate the effect ... the environmental impact on the air and soil. The initiative ... BATFARM European project.. The mobile laboratory is equipped with ... A photoacoustic gas analyser will be used to monitor in ...
... and mosquitoes share similar sensory receptors that allow them to ... chemical odors as they search for food or try ... report in the current electronic edition of the journal ... found on the surfaces of neurons that give the fruit ...
Cached Biology News:Healthy piglets? Not with sulfonamides! 2Neiker-Tecnalia sets up a mobile laboratory to reduce the environmental impact of farms 2Senses of sophistication: Mosquitoes detect subtle cues finding food, spreading diseases 2
... plastic tray. Ideal for staining westerns and ... for multipurposes. Pour spouts in each corner ... label may be used for identification. Lid ... or shakers for staining several gels simultaneously. ...
... Vivaclear centrifugal filters are disposable microfiltration devices ... samples in the range 100 l to 500 ... rotors accepting 2.2 ml centrifuge tubes. Product Features: ... pore size Low hold up volume ...
... The ClearSpin Filter is a novel ... aid the clarification of bacterial lysates in ... Filter is a novel, disposable spin filtration ... of bacterial lysates in plasmid purification procedures. ...
... fixed-angle microcentrifuge rotor at RCF up ... filters consist of a membrane-containing filter ... filter by centrifugation for bacteria removal, ... of cells from media and DNA ...
Biology Products: